Sponsors (6)
The bill improves access and payment clarity for IVIG treatment for Medicare patients with primary immunodeficiency and allows adaptable coding updates, but it increases Medicare/taxpayer spending and imposes implementation work on CMS and providers.
Medicare beneficiaries with primary immunodeficiency: starting Oct 1, 2026, IVIG treatments and related services will be covered under the specified payment rule, improving access to needed care.
Hospitals and outpatient providers (and state payers): the bill clarifies payment coverage for specified IVIG HCPCS codes and allows the HHS Secretary to update the HCPCS list after Jan 1, 2026, reducing billing uncertainty and enabling timely coverage adjustments as new IVIG products emerge.
Taxpayers and the Medicare program: federal spending is likely to increase to cover IVIG and related services beginning Oct 1, 2026, raising program costs and fiscal pressure.
Medicare beneficiaries and taxpayers: if future HCPCS updates expand coverage to higher‑cost IVIG formulations, program expenditures (and potentially beneficiary costs) could rise further absent explicit cost-control measures.
CMS, state governments, and providers: implementing the coding and payment updates before the Oct 1, 2026 effective date will create administrative and operational work for CMS and health systems.
Based on analysis of 2 sections of legislative text.
Adds specified IVIG products and related services for primary immunodeficiency into an existing Medicare payment provision, with listed HCPCS codes and Secretary update authority.
Adds specified intravenous immune globulin (IVIG) products and associated items and services used to treat primary immunodeficiency disease to an existing Medicare payment rule. The change names specific HCPCS codes (as of Jan 1, 2026, and as later updated by the Secretary) and applies to items and services furnished on or after October 1, 2026.
Official title: To amend title XVIII of the Social Security Act to improve access to skilled nursing facilities for primary immunodeficiency patients.
Introduced April 27, 2026 by Adrian Smith · Last progress April 27, 2026